Vivien Veninga

Vivien Veninga

Auto-generated profile, based on publicly available information

Vivien Veninga

Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Cancer Cell
Verified
Journal Article
Closed access
VVVivien Veninga
Vivien Veninga
EVE.E. Voest
E.E. Voest

11 January 2023 in Nature
Verified
Journal Article
Open access
PDF file
NVNatasja L. de Vries
Natasja L. de Vries
JHJoris van de Haar
Joris van de Haar
VVVivien Veninga
Vivien Veninga
MCMyriam Chalabi
Myriam Chalabi
MIMarieke E. Ijsselsteijn
Marieke E. Ijsselsteijn
EVE.E. Voest
E.E. Voest
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)1,2. Here, in contrast to other cancer types3–5, we observed that 20 out of 21 (95%) MMR-d cancers with genomic inactivation of β2-microglobulin (encoded by B2M) retained responsiveness to ICB, suggesting the involvement of immune effector cells other than CD8+ T cells in this context. We next identified a strong association between B2M inactivation and increased infiltration by γδ T cells in MMR-d cancers. These γδ T cells mainly comprised the Vδ1 and Vδ3 subsets, and expressed high levels of PD-1, other activation markers, including cytotoxic molecules, and a broad repertoire of killer-cell immunoglobulin-like receptors. In vitro, PD-1+ γδ T cells that were isolated from MMR-d colon cancers exhibited enhanced reactivity to human leukocyte antigen (HLA)-class-I-negative MMR-d colon cancer cell lines and B2M-knockout patient-derived tumour organoids compared with antigen-presentation-proficient cells. By comparing paired tumour samples from patients with MMR-d colon cancer that were obtained before and after dual PD-1 and CTLA-4 blockade, we found that immune checkpoint blockade substantially increased the frequency of γδ T cells in B2M-deficient cancers. Taken together, these data indicate that γδ T cells contribute to the response to immune checkpoint blockade in patients with HLA-class-I-negative MMR-d colon cancers, and underline the potential of γδ T cells in cancer immunotherapy.

15 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
NVNatasja L. de Vries
Natasja L. de Vries
JHJoris van de Haar
Joris van de Haar
VVVivien Veninga
Vivien Veninga
MCMyriam Chalabi
Myriam Chalabi
MIMarieke Erica Ijsselsteijn
Marieke Erica Ijsselsteijn
EVE.E. Voest
E.E. Voest
DNA mismatch repair deficient (MMR-d) cancers present an abundance of neoantigens that likely underlies their exceptional responsiveness to immune checkpoint blockade (ICB) 1,2 . However, MMR-d colon cancers that evade CD8 + T cells through loss of Human Leukocyte Antigen (HLA) class I-mediated antigen presentation 3–6 , frequently remain responsive to ICB 7 suggesting the involvement of other immune effector cells. Here, we demonstrate that HLA class I-negative MMR-d cancers are highly infiltrated by γδ T cells. These γδ T cells are mainly composed of Vδ1 and Vδ3 subsets, and express high levels of PD-1, activation markers including cytotoxic molecules, and a broad repertoire of killer-cell immunoglobulin-like receptors (KIRs). In vitro , PD-1 + γδ T cells, isolated from MMR-d colon cancers, exhibited a cytolytic response towards HLA class I-negative MMR-d colon cancer cell lines and β 2 - microglobulin ( B2M )-knockout patient-derived tumor organoids (PDTOs), which was enhanced as compared to antigen presentation-proficient cells. This response was diminished after blocking the interaction between NKG2D and its ligands. By comparing paired tumor samples of MMR-d colorectal cancer patients obtained before and after dual PD-1 and CTLA-4 blockade, we found that ICB profoundly increased the intratumoral frequency of γδ T cells in HLA class I-negative cancers. Taken together, these data indicate that γδ T cells contribute to the response to ICB therapy in patients with HLA class I-negative, MMR-d colon cancers, and illustrate the potential of γδ T cells in cancer immunotherapy.